Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

LabGenius Therapeutics appoints three experts to its team of scientific advisors

Pioneering therapeutic antibody optimization, LabGenius Therapeutics utilizes advanced technologies to improve drug development and clinical translation.

From LabGenius 27 Feb 2025

Microphysiological systems in drug discovery

NewsMedical speaks with CN Bio about the translatability between in vitro organ-on-a-chip (OOC) models, microphysiological systems, and their in vivo counterparts.

From CN Bio 26 Feb 2025

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).

25 Feb 2025

Breakthrough method opens door to fluorinated oxetane drug molecules

Researchers from the National University of Singapore (NUS) have pioneered a new catalytic transformation that converts epoxides into fluorinated oxetanes, a coveted but difficult-to-make class of drug molecules that escaped synthetic preparation for years.

22 Feb 2025

New computational tool iDOMO improves prediction of drug synergy

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.

22 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Boston University professor receives grant for preeclampsia drug discovery research

Wendy Kuohung, MD, associate professor of obstetrics & gynecology at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, Discovery Research Grant from March of Dimes.

21 Feb 2025

Sapio Sciences Expands Leadership Team to Drive Growth

The appointment of Mike Hampton and the launch of a Scientific Office position Sapio Sciences at the forefront of AI-driven lab informatics and drug discovery.

From Sapio Sciences 20 Feb 2025

New research sheds light on brain inflammation in Alzheimer's

Brain inflammation, while a crucial part of the body's immune response, takes on a detrimental role in Alzheimer's disease.

16 Feb 2025

A step toward precision medicine: New drug targets for heart failure

Researchers identify several promising drug targets for heart failure and its clinical subtypes.

14 Feb 2025

Insilico Medicine announces preclinical drug discovery benchmarks from 2021 to 2024

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 developmental candidate nominations achieved by its platform from 2021 to 2024.

11 Feb 2025

Breakthrough study identifies new way to address Alzheimer's at early stages

A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers cellular inflammation and aging and is linked to Alzheimer's disease, particularly among those who carry the APOE4 genetic risk.

10 Feb 2025

Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma.

7 Feb 2025

Study reveals differences in allosteric behavior of cAMP receptor proteins in M. tuberculosis

A new study, "Identifying Allosteric Hotspots in Mycobacterium tuberculosis cAMP Receptor Protein" published in Biochemistry, provides key insights into how bacterial cAMP receptor proteins (CRPs) respond differently to the ubiquitous signaling molecule, cyclic AMP (cAMP).

7 Feb 2025

New method for detecting inflammation could revolutionize disease diagnosis

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues in the human body.

6 Feb 2025

New study identifies potential drug targets for heart failure

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart failure is classified into two major clinical subtypes- heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).

6 Feb 2025

Optibrium widens access to industry-leading docking method

Optibrium, a leading developer of software and AI solutions for molecular design today announced the introduction of a new PyMOL Graphical User Interface (GUI) for Surflex-Dock, its industry-leading structure-based design method, which is part of the company’s BioPharmics 3D molecular modelling suite.

5 Feb 2025

CN Bio launches physioMimix DILI assay kit: Human 24, for enhanced preclinical toxicology testing

CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® DILI assay kit: Human 24.

5 Feb 2025

New insights into how the Sudan virus attaches to human cells

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist.

4 Feb 2025